Evaluation of Efficiency in the Activation and Accrual of Interventional Clinical Trials at Cancer Centers
Background: Clinical trials represent a significant percentage of the time and cost to bring a drug through the development process and to Food and Drug Administration approval. Despite how critical these trials are to the drug development process, many studies are underpowered due to low accrual....
Main Author: | Tate, Wendy Rose |
---|---|
Other Authors: | Abraham, Ivo |
Language: | en_US |
Published: |
The University of Arizona.
2016
|
Subjects: | |
Online Access: | http://hdl.handle.net/10150/612064 http://arizona.openrepository.com/arizona/handle/10150/612064 |
Similar Items
-
Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations
by: Tilde Dombernowsky, et al.
Published: (2019-12-01) -
NCI–Clinical Trial Accrual in a Community Network Affiliated with a Designated Cancer Center
by: Daniel J. Kim, et al.
Published: (2020-06-01) -
Partnering around cancer clinical trials (PACCT): study protocol for a randomized trial of a patient and physician communication intervention to increase minority accrual to prostate cancer clinical trials
by: Susan Eggly, et al.
Published: (2017-12-01) -
The Investigational Clinical Center: a clinical-supportive and patient-centered trial unit model. Ten years of experience through normal and pandemic times of a large pediatric trial center in Italy
by: Giuseppe Pontrelli, et al.
Published: (2021-07-01) -
Clinical Trial Accrual: Obstacles and Opportunities
by: BJ eRimel
Published: (2016-04-01)